![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 18
2022
Buske, C.; Dreyling, M.; Alvarez-Larran, A.; Apperley, J.; Arcaini, L.; Besson, C.; Bullinger, L.; Corradini, P.; Della Porta, M. Giovanni; Dimopoulos, M.; D'Sa, S.; Eich, H. T.; Foa, R.; Ghia, P.; da Silva, M. G.; Gribben, J.; Hajek, R.; Harrison, C.; Heuser, M.; Kiesewetter, B.; Kiladjian, J. J.; Kroeger, N.; Moreau, P.; Passweg, J. R.; Peyvandi, F.; Rea, D.; Ribera, J.-M.; Robak, T.; San-Miguel, J. F.; Santini, V.; Sanz, G.; Sonneveld, P.; Lilienfeld-Toal, M. von; Wendtner, C.; Pentheroudakis, G. und Passamonti, F.
(2022):
Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus.
In: ESMO Open, Bd. 7, Nr. 2, 100403
2017
Altamura, S.; Vegi, N.; Hültner, L.; Schneider, M.; Hoppe, P.; Schröder, T.; Canli, O.; Greten, F.; Aichler, M.; Walch, A.; Neff, F.; Janik, D.; Kuklik-Roos, C.; Ladinig, C.; Mysliwietz, J.; Rathkolb, B.; Buske, C.; Conrad, M.; Muckenthaler, M. und Bornkamm, G.
(2017):
Lack of the Ferroptosis inhibitor GPX4 in erythroid cells causes a block in reticulocyte maturation and a hypoxic signature with impaired Hepcidin regulation.
In: Haematologica, Bd. 102: S. 333
2016
Witzens-Harig, M.; Keller, U.; Viardot, A.; Buske, C.; Hönig, E.; Crombe, A.; Brandt, J.; Meissner, J.; Ho, A.; La Rosee, P.; Marks, R.; Dreyling, M. und Hess, G.
(2016):
Safety and clinical activity of temsirolimus in combination with Rituximab and DHAP in patients with relapsed or refractory diffuse large B-cell lymphoma - preliminary results of the storm trial.
In: Haematologica, Bd. 101: S. 390
Ladetto, M.; Buske, C.; Hutchings, M.; Dreyling, M.; Gaidano, G.; Le Gouill, S.; Luminari, S.; Pott, C.; Zamò, A. und Zucca, E.
(2016):
ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia.
In: Annals of Oncology, Bd. 27, Nr. 12: S. 2149-2160
Feder, K.; Edmaier, K.; Eshraghi, P.; Vegi, N.; Mulaw, M.; Ihme, S.; Spiekermann, K.; Metzeler, K.; Hiddemann, W.; Döhner, K.; Döhner, H.; Feuring-Buske, M. und Buske, C.
(2016):
The Lef1 isoform, lacking the β-catenin binding domain, is not acting as a dominant negative Lef1 variant, but is a hematopoietic active protein with unique DNA binding properties.
In: Oncology Research and Treatment, Bd. 39: S. 46
2012
Schneider, F.; Hoster, Eva; Schneider, S.; Dufour, A.; Benthaus, T.; Kakadia, P. M.; Bohlander, Stefan K.; Braess, J.; Heinecke, A.; Sauerland, M. C.; Berdel, W. E.; Büchner, T.; Wörmann, Bernhard; Feuring-Buske, M.; Buske, C.; Creutzig, U.; Thiede, C.; Zwaan, M. C.; Heuvel-Eibrink, M. M. van den; Reinhardt, D.; Hiddemann, Wolfgang und Spiekermann, Karsten
(2012):
Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML).
In: Annals of Hematology, Bd. 91, Nr. 1: S. 9-18
Schneider, F.; Hoster, Eva; Unterhalt, Michael; Schneider, S.; Dufour, A.; Benthaus, T.; Mellert, G.; Zellmeier, Evelyn; Kakadia, P. M.; Bohlander, Stefan K.; Feuring-Buske, M.; Buske, C.; Braess, J.; Heinecke, A.; Sauerland, M. C.; Berdel, W. E.; Büchner, T.; Wörmann, Bernhard; Hiddemann, Wolfgang und Spiekermann, Karsten
(2012):
The FLT3ITD level has a high prognostic impact in NPM1 mutated, but not NPM1 unmutated AML with a normal karyotype.
In: Blood, Bd. 119, Nr. 19: S. 4383-4386
Herold, Tobias; Mulaw, M. A.; Jurinovic, Vindi; Seiler, T.; Metzeler, Klaus H.; Dufour, A.; Schneider, S.; Kakadia, P. M.; Spiekermann, Karsten; Mansmann, Ulrich; Hiddemann, Wolfgang; Buske, C.; Dreyling, Martin und Bohlander, Stefan K.
(2012):
High expression of MZB1 predicts adverse prognosis in chronic lymphocytic leukemia, follicular lymphoma and diffuse large B-cell lymphoma and is associated with a unique gene expression signature.
In: Leukemia & Lymphoma, Bd. 54, Nr. 8: S. 1652-1657
2011
Herold, Tobias; Jurinovic, Vindi; Metzeler, Klaus H.; Boulesteix, Anne-Laure; Bergmann, M.; Seiler, T.; Mulaw, M.; Thoene, S.; Dufour, A.; Pasalic, Z.; Schmidberger, Markus; Schmidt, M.; Schneider, S.; Kakadia, P. M.; Feuring-Buske, M.; Braess, J.; Spiekermann, Karsten; Mansmann, Ulrich; Hiddemann, Wolfgang; Buske, C. und Bohlander, Stefan K.
(2011):
An eight-gene expression signature for the prediction of survival and time to treatment in chronic lymphocytic leukemia.
In: Leukemia, Bd. 25, Nr. 10: S. 1639-1645
Herold, Tobias; Jurinovic, Vindi; Mulaw, M.; Seiler, T.; Dufour, A.; Schneider, S.; Kakadia, P. M.; Feuring-Buske, M.; Braess, J.; Spiekermann, Karsten; Mansmann, Ulrich; Hiddemann, Wolfgang; Buske, C. und Bohlander, Stefan K.
(2011):
Expression analysis of genes located in the minimally deleted regions of 13q14 and 11q22-23 in chronic lymphocytic leukemia-unexpected expression pattern of the RHO GTPase activator ARHGAP20.
In: Genes, Chromosomes and Cancer, Bd. 50, Nr. 7: S. 546-558
2009
Thoene, S.; Rawat, V. P.; Heilmeier, B.; Hoster, Eva; Metzeler, Klaus H.; Herold, Tobias; Hiddemann, Wolfgang; Gökbuget, Nicola; Hoelzer, D.; Bohlander, Stefan K.; Feuring-Buske, M. und Buske, C.
(2009):
The homeobox gene CDX2 is aberrantly expressed and associated with an inferior prognosis in patients with acute lymphoblastic leukemia.
In: Leukemia, Bd. 23, Nr. 4: S. 649-655
Reiff, T.; Stingele, R.; Eckstein, H. H.; Fraedrich, G.; Jansen, O.; Mudra, H.; Mansmann, Ulrich; Hacke, W.; Ringleb, P. A.; Metzeler, Klaus H.; Dufour, A.; Benthaus, T.; Hummel, Martina; Sauerland, M. C.; Heinecke, A.; Berdel, W. E.; Büchner, T.; Wörmann, Bernhard; Braess, J.; Spiekermann, Karsten; Hiddemann, Wolfgang; Buske, C.; Bohlander, Stefan K.; Nagel, J. M.; Wegscheider, K.; Rohmel, J.; Fleckenstein, M.; Adrion, Christine 
ORCID: https://orcid.org/0000-0003-2408-2533; Schmitz-Valckenberg, S.; Gobel, A. P.; Bindewald-Wittich, A.; Scholl, H. und Holz, F.
(2009):
Stent-Protected Angioplasty in Asymptomatic Carotid Artery Stenosis vs. Endarterectomy: SPACE2 – a Three-Arm Randomised-Controlled Clinical Trial.
In: International Journal of Stroke, Bd. 4, Nr. 4: S. 294-299
ORCID: https://orcid.org/0000-0003-2408-2533; Schmitz-Valckenberg, S.; Gobel, A. P.; Bindewald-Wittich, A.; Scholl, H. und Holz, F.
(2009):
Stent-Protected Angioplasty in Asymptomatic Carotid Artery Stenosis vs. Endarterectomy: SPACE2 – a Three-Arm Randomised-Controlled Clinical Trial.
In: International Journal of Stroke, Bd. 4, Nr. 4: S. 294-299
Schneider, F.; Hoster, Eva; Unterhalt, Michael; Schneider, S.; Dufour, A.; Benthaus, T.; Mellert, G.; Zellmeier, Evelyn; Bohlander, Stefan K.; Feuring-Buske, M.; Buske, C.; Braess, J.; Fritsch, S.; Heinecke, A.; Sauerland, M. C.; Berdel, W. E.; Büchner, T.; Wörmann, Bernhard; Hiddemann, Wolfgang und Spiekermann, Karsten
(2009):
NPM1, but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high risk myelodysplastic syndrome (MDS).
In: Blood, Bd. 113, Nr. 21: S. 5250-5253
Buske, C.; Hoster, Eva; Dreyling, Martin; Eimermacher, H.; Wandt, H.; Metzner, B.; Fuchs, R.; Bittenbring, J.; Wörmann, Bernhard; Hohloch, K.; Hess, G.; Ludwig, W. D.; Schimke, J.; Schmitz, S.; Kneba, M.; Reiser, M.; Graeven, U.; Klapper, Wolfram; Unterhalt, Michael und Hiddemann, Wolfgang
(2009):
The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG).
In: Leukemia, Bd. 23, Nr. 1: S. 153-161
Metzeler, Klaus H.; Dufour, A.; Benthaus, T.; Hummel, Martina; Sauerland, M. C.; Heinecke, A.; Berdel, W. E.; Büchner, T.; Wörmann, Bernhard; Mansmann, Ulrich; Braess, J.; Spiekermann, Karsten; Hiddemann, Wolfgang; Buske, C. und Bohlander, Stefan K.
(2009):
ERG Expression Is an Independent Prognostic Factor and Allows Refined Risk Stratification in Cytogenetically Normal Acute Myeloid Leukemia: A Comprehensive Analysis of ERG, MN1, and BAALC Transcript Levels Using Oligonucleotide Microarrays.
In: Journal of Clinical Oncology, Bd. 27, Nr. 30: S. 5031-5038
2008
Hummel, Manuela; Metzeler, Klaus H.; Buske, C.; Bohlander, Stefan K. und Mansmann, Ulrich
(2008):
Association between a Prognostic Gene Signature and Functional Gene Sets.
In: Bioinformatics and Biology Insights, Bd. 2: S. 329-341
Metzeler, Klaus H.; Hummel, Martina; Bloomfield, C. D.; Spiekermann, Karsten; Braess, J.; Sauerland, M. C.; Heinecke, A.; Radmacher, M. D.; Marcucci, G.; Whitman, SP.; Maharry, K.; Paschka, P.; Larson, RA.; Berdel, W. E.; Büchner, T.; Wörmann, Bernhard; Mansmann, Ulrich; Hiddemann, Wolfgang; Bohlander, Stefan K. und Buske, C.
(2008):
An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia.
In: Blood, Bd. 112, Nr. 10: S. 4193-4201
2006
Buske, C.; Hoster, Eva; Dreyling, Martin; Hasford, Joerg; Unterhalt, Michael und Hiddemann, Wolfgang
(2006):
The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vinc.
In: Blood, Bd. 108, Nr. 5: S. 1504-1508